• Dopamine agonist therapy using se lected drugs at particular dosage levels has been found to have therapeutic benefit in certain dyskinetic syndromes. Two ergot derivatives with dopamine agonist properties were administered at relatively low doses to eight neuroleptic-free schizophrenic patients with tardive dyskinesia. Neither agent significantly improved dyskinetic symptoms; no symptoms worsened. Dopamine agonists likely vary in their selective activation of functionally distinct dopamine receptors.
Tamminga CA, Chase TN. Bromocriptine and CF 25-397 in the Treatment of Tardive Dyskinesia. Arch Neurol. 1980;37(4):204–205. doi:10.1001/archneur.1980.00500530042004
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.